Research Article
Management of Respiratory Syncytial Virus Bronchiolitis: 2015 Survey of Members of the European Society for Paediatric Infectious Diseases
Table 2
Number (%) of doctors advising various interventions to manage infants with RSV bronchiolitis in various settings.
| | | Bronchodilators via inhaler | Bronchodilators via nebuliser | Nebulised adrenaline | Steroids via inhaler | Steroids via nebuliser | Oral steroids | Heliox | Montelukast | Nebulised hypertonic saline | Antibiotics | Ribavirin | RSV intravenous immunoglobulin | Palivizumab | Chest physiotherapy | Nasal suctioning | Naso-/orogastric feeding | Intravenous fluids |
| | Most patients with bronchiolitis (whether admitted to an inpatient ward or discharged home) | 18 (17%) | 14 (13%) | 9 (8%) | 4 (4%) | 4 (4%) | 2 (2%) | 0 (0%) | 1 (1%) | 20 (18%) | 3 (3%) | 1 (1%) | 0 (0%) | 0 (0%) | 4 (4%) | 19 (17%) | 1 (1%) | 6 (6%) | | Most patients with bronchiolitis admitted to an inpatient ward | 6 (6%) | 25 (23%) | 14 (13%) | 1 (1%) | 3 (3%) | 2 (2%) | 1 (1%) | 0 (0%) | 29 (27%) | 4 (4%) | 0 (0%) | 0 (0%) | 2 (2%) | 6 (6%) | 43 (39%) | 21 (19%) | 18 (17%) | | Most patients with severe bronchiolitis (i.e., requiring high dependency/intensive care) | 5 (5%) | 17 (16%) | 27 (25%) | 9 (8%) | 11 (10%) | 19 (17%) | 10 (9%) | 6 (6%) | 13 (12%) | 22 (20%) | 5 (5%) | 5 (5%) | 3 (3%) | 16 (15%) | 20 (18%) | 53 (49%) | 62 (57%) | | Other indications in infants with bronchiolitis | 20 (18%) | 18 (17%) | 11 (10%) | 11 (10%) | 3 (3%) | 11 (10%) | 1 (1%) | 4 (4%) | 12 (11%) | 26 (24%) | 8 (7%) | 2 (2%) | 6 (6%) | 11 (10%) | 6 (6%) | 12 (11%) | 17 (16%) | | Not administered to any patient with bronchiolitis | 60 (55%) | 35 (32%) | 48 (44%) | 84 (77%) | 88 (81%) | 75 (69%) | 97 (89%) | 98 (90%) | 35 (32%) | 54 (50%) | 95 (87%) | 102 (94%) | 98 (90%) | 72 (66%) | 21 (19%) | 22 (20%) | 6 (6%) |
|
|
